FDA's MDMA Rejection: A Setback for Psychedelic-Assisted Therapy?
- The Reset Center
- Sep 16, 2024
- 1 min read
The FDA’s rejection of MDMA for PTSD treatment could have far-reaching implications for other psychedelics, including psilocybin. The decision signals the FDA’s high level of scrutiny when it comes to psychedelic therapies, particularly regarding issues of safety, trial design, and data integrity. As Dr. Michael Louwers, MD at Reset Medical and Wellness Center, explained, “The recent rejection of MDMA for PTSD treatment highlights the importance of high-quality, evidence-based testing. With further research, psychedelic medicines can have a very beneficial impact on the mental health community.”